Download PDF
Thromb Haemost 1961; 6(03): 411-423
DOI: 10.1055/s-0038-1654573
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Effect of Surface and Hageman Factor on the Endogenous or Spontaneous Activation of the Fibrinolytic System[*]

Sotirios G. Iatridis   **
1   Dept. of Physiology, School of Medicine, Univ. of North Carolina, Chapel Hill, N. C.
,
John H. Ferguson
1   Dept. of Physiology, School of Medicine, Univ. of North Carolina, Chapel Hill, N. C.
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

    Permissions and Reprints

Summary

The effect of wettable surfaces and Hageman factor on the activation of the fibrinolytic system was investigated.

The fibrinolytic activity was estimated mainly by the euglobulin lysis test. Experiments were carried out with Normal and Hageman-deficient plasmas.

The euglobulin lysis time of both plasmas was greatly affected by varying the surface exposure. Normal euglobulin suspension incubated at 37° C, and tested at intervals, showed an increase of fibrinolytic activity. The evidence suggests that this activity is related to the generation of endogenous activator. The rate of generation was a function of surface. Hageman-deficient euglobulin suspension, under the same conditions, did not generate endogenous activator.

Evidence is presented to show that Hageman factor is different from proactivator and plasminogen.

It is concluded that wettable surfaces and Hageman factor may have a role in the endogenous (or spontaneous) activation of the fibrinolytic system.

* Aided by a grant (H 1510—C7) from the N. I. H. Division of Research Grants and Fellowships, U. S. P. H. S.


** This work was carried out during the tenure of an appointment supported by the International Cooperation Administration, under the Visiting Research Scientists Program administered by the National Academy of Sciences of the United States of America.


 

  • References

  • (1) Sherry S, Fletcher A. P, Alkjaersig N. Fibrinolysis and fibrinolytic activity in man. Physiol. Rev. 39: 343 1959;
    CrossrefPubMedGoogle Scholar
  • (2) Müllertz S. Activation of plasminogen. Ann. N. Y. Acad. Sci. 68: 38 1957;
    CrossrefPubMedGoogle Scholar
  • (3) Sawyer W. D, Fletcher A. P, Alkjaersig N, Sherry S. Studies on the thrombolytic activity of human plasma. J. clin. Invest. 39: 426 1960;
    CrossrefPubMedGoogle Scholar
  • (4) Sherry S, Lindemeyer R. I, Fletcher A. P, Alkjaersig N. Enhanced fibrinolytic activity in man. J. clin. Invest. 38: 810 1959;
    CrossrefPubMedGoogle Scholar
  • (5) Alkjaersig N, Fletcher A. P, Sherry S. The mechanism of clot dissolution by plasmin. J. clin. Invest. 38: 1086 1959;
    CrossrefPubMedGoogle Scholar
  • (6) Fletcher A. P, Sherry S. Thrombolytic (fibrinolytic) therapy for coronary heart disease. Circulation 22: 619 1960;
    CrossrefPubMedGoogle Scholar
  • (7) Ferguson J. H, Wilson E. G, Iatridis S. G, Rierson H. A, Johnston B. R. Enzymes and blood clotting. I. Trypsin as an accessory factor. J. clin. Invest. 39: 1942 1960;
    CrossrefPubMedGoogle Scholar
  • (8) Johnston Jr C. L, Ferguson J. H, O’Hanlon F. A. Surface activation of plasma clotting: a function of Hageman factor. Proc. Soc. exp. Biol. (N. Y.) 99: 197 1958;
    CrossrefPubMedGoogle Scholar
  • (9) Iatridis S. G, Wilson E. G, Ferguson J. H, Rierson H. A. Blood clotting activities of thrombolytic agents with special reference to a Hageman-like effect. Thromb. Diath. haem. 5: 50 1960;
    PubMedGoogle Scholar
  • (10) Astrup T, Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Arch. Biochem. 40: 345 1952;
    PubMedGoogle Scholar
  • (11) Alkjaersig N, Fletcher A. P, Sherry S. E-aminocaproic acid: and inhibitor of plasminogen activation. J. biol. Chem. 234: 832 1959;
    PubMedGoogle Scholar
  • (12) Langdell R. D, Wagner R. H, Brinkhous K. M. Effect of antihemophilic factor on one-stage clotting tests. A presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. J. Lab. clin. Med. 41: 637 1953;
    PubMedGoogle Scholar
  • (13) Müllertz S. Formation and properties of the activator of plasminogen and of human and bovine plasmin. Biochem. J. 61: 424 1955;
    CrossrefPubMedGoogle Scholar
  • (14) Iatridis S. G. The effects of surface on plasminogen activation. Fed. Proc. 20: 58 1961;
    PubMedGoogle Scholar
  • (15) Lewis J. H, Ferguson J. H. Studies on a proteolytic enzyme system of the blood. IV. Activation of profibrinolysin by serum fibrinolysokinase. Proc. Soc. exp. Biol. (N. Y.) 78: 184 1951;
    CrossrefPubMedGoogle Scholar
  • (16) Müllertz S, Lassen M. An activator system in blood indispensable for formation of plasmin by streptokinase. Proc. Soc. exp. Biol. (N. Y.) 82: 264 1953;
    CrossrefPubMedGoogle Scholar
  • (17) Müllertz S. A plasminogen activator in spontaneously active human blood. Proc. Soc. exp. Biol. (N. Y.) 82: 291 1953;
    CrossrefPubMedGoogle Scholar
  • (18) Ratnoff O. D. Fibrinogen and fibrin as substrates for the proteolytic enzyme of plasma. J. clin. Invest. 32: 473 1953;
    CrossrefPubMedGoogle Scholar
  • (19) Niewiarowski S, Prou-Wartelle O. Rôle du facteur contact (facteur Hageman) dans la fibrinolyse. Thromb. Diath. haem. 3: 593 1959;
    PubMedGoogle Scholar